UNLABELLED: Barth syndrome is an X-linked disorder usually diagnosed in infancy. It is characterized by hypotonia, dilated cardiomyopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria. The syndrome is typically caused by mutations in the TAZ (G4.5) gene, which encodes a novel protein family called the tafazzins. We report the case of two brothers with Barth syndrome and left ventricular noncompaction (LVNC) caused by a splice donor mutation in TAZ. Both had impaired sucking ability at the age of 2 months. The elder brother was diagnosed with LVNC at the age of 4 months; by that time he had developed severe heart failure with metabolic decompensation. He died at 12 months of age due to intractable heart failure despite pharmacological therapy with diuretics, an angiotensin-converting enzyme inhibitor, and a beta-blocker. However, the younger brother, who was diagnosed as having Barth syndrome and LVNC with heart failure at the age of 2 months, received early medical treatment and demonstrated normal echocardiographic findings. CONCLUSION: The clinical courses of Barth syndrome observed in our cases show the phonotypic variability of this syndrome and suggest that early therapy may be beneficial for maintaining cardiac function.
UNLABELLED: Barth syndrome is an X-linked disorder usually diagnosed in infancy. It is characterized by hypotonia, dilated cardiomyopathy, neutropenia, growth retardation, and 3-methylglutaconic aciduria. The syndrome is typically caused by mutations in the TAZ (G4.5) gene, which encodes a novel protein family called the tafazzins. We report the case of two brothers with Barth syndrome and left ventricular noncompaction (LVNC) caused by a splice donor mutation in TAZ. Both had impaired sucking ability at the age of 2 months. The elder brother was diagnosed with LVNC at the age of 4 months; by that time he had developed severe heart failure with metabolic decompensation. He died at 12 months of age due to intractable heart failure despite pharmacological therapy with diuretics, an angiotensin-converting enzyme inhibitor, and a beta-blocker. However, the younger brother, who was diagnosed as having Barth syndrome and LVNC with heart failure at the age of 2 months, received early medical treatment and demonstrated normal echocardiographic findings. CONCLUSION: The clinical courses of Barth syndrome observed in our cases show the phonotypic variability of this syndrome and suggest that early therapy may be beneficial for maintaining cardiac function.
Authors: S S Adwani; B F Whitehead; P G Rees; A Morris; D M Turnball; M J Elliott; M R de Leval Journal: Pediatr Cardiol Date: 1997 Mar-Apr Impact factor: 1.655
Authors: R I Kelley; J P Cheatham; B J Clark; M A Nigro; B R Powell; G W Sherwood; J T Sladky; W P Swisher Journal: J Pediatr Date: 1991-11 Impact factor: 4.406
Authors: Carolyn T Spencer; Randall M Bryant; Jane Day; Iris L Gonzalez; Steven D Colan; W Reid Thompson; Julie Berthy; Sharon P Redfearn; Barry J Byrne Journal: Pediatrics Date: 2006-07-17 Impact factor: 7.124
Authors: Riekelt H Houtkooper; Richard J Rodenburg; Charlotte Thiels; Henk van Lenthe; Femke Stet; Bwee Tien Poll-The; Janet E Stone; Colin G Steward; Ronald J Wanders; Jan Smeitink; Willem Kulik; Frédéric M Vaz Journal: Anal Biochem Date: 2009-01-31 Impact factor: 3.365
Authors: Peter G Barth; Fredoen Valianpour; Valerie M Bowen; Jan Lam; Marinus Duran; Frédéric M Vaz; Ronald J A Wanders Journal: Am J Med Genet A Date: 2004-05-01 Impact factor: 2.802
Authors: C G Steward; R A Newbury-Ecob; R Hastings; S F Smithson; B Tsai-Goodman; O W Quarrell; W Kulik; R Wanders; M Pennock; M Williams; J L Cresswell; I L Gonzalez; P Brennan Journal: Prenat Diagn Date: 2010-10 Impact factor: 3.050
Authors: Yasuhiro Kosaka; Katarzyna A Cieslik; Ling Li; George Lezin; Colin T Maguire; Yukio Saijoh; Kazuhito Toyo-oka; Michael J Gambello; Matteo Vatta; Anthony Wynshaw-Boris; Antonio Baldini; H Joseph Yost; Luca Brunelli Journal: Mol Cell Biol Date: 2012-10-15 Impact factor: 4.272